Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months and Full Year of Fiscal Year Ending March 31, 2021
August 04, 2020 at 12:30 pm IST
Share
Zeria Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the six months and full year of fiscal year ending March 31, 2021. For the six months, the company expects net sales of ¥28,000 million, operating profit of ¥1,700 million, profit attributable to owners of parent of ¥1,500 million, basic earnings per share of ¥32.46.
For the full year, the company expects net sales of ¥61,000 million, operating profit of ¥4,300 million, profit attributable to owners of parent of ¥3,300 million, basic earnings per share of ¥71.47.
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
ZERIA PHARMACEUTICAL CO., LTD. 
